Ocrevus Zunovo: Dry Eye and Vision-Symptom Guidance

Ocrevus Zunovo is a multiple sclerosis (MS) treatment, not an eye drop or a dry-eye treatment. If you develop burning eyes or blurred vision while receiving it, do not automatically assume either dry eye or a drug side effect. Dry eye, MS-related vision problems and certain infections can cause overlapping symptoms but need different care.

What is Ocrevus Zunovo?

Ocrevus Zunovo contains ocrelizumab and hyaluronidase-ocsq. In the United States, it is approved for adults with relapsing forms of MS—including clinically isolated syndrome, relapsing-remitting MS and active secondary progressive MS—and for adults with primary progressive MS. Ocrelizumab targets certain immune cells called B cells. U.S. prescribing information, revised September 2026

Unlike intravenous Ocrevus, Zunovo is injected under the skin of the abdomen by a healthcare professional. The injection takes approximately 10 minutes and is given every six months. The appointment takes longer than the injection: premedication is required at least 30 minutes beforehand, followed by observation for at least one hour after the first injection and at least 15 minutes after later injections. It is not a self-injection treatment. Dosage and administration

Does Ocrevus Zunovo cause dry eye?

Dry eye is not listed among the common adverse reactions in the September 2026 U.S. label. Injection reactions are the most common reaction reported in the Zunovo trial. The label also describes infection risks associated with ocrelizumab. Not being listed as common does not prove that a medicine cannot contribute to an individual’s symptoms. Adverse reactions

Dry eye itself can cause scratchiness, burning, redness and blurry vision. It happens when there are too few tears or when tears do not work properly. An eye examination can assess tear production, tear stability and eyelid structure. National Eye Institute

MS can also affect vision independently of treatment. For example, optic neuritis—inflammation of the optic nerve—can cause pain with eye movement and vision loss. MS may also cause double vision. These are not problems that lubricating drops treat. National Institute of Neurological Disorders and Stroke

Which eye symptoms need prompt care?

Seek same-day clinician attention for sudden vision changes, eye pain or new light sensitivity. Seek emergency care for severe eye pain, eye pain accompanied by sudden vision changes or increased light sensitivity, or sudden vision loss—even if it is painless. Do not wait to see whether dry-eye drops help. Mayo Clinic eye-pain guidance; Cleveland Clinic sudden-vision-loss guidance

Two warnings in the Ocrevus Zunovo label are particularly relevant:

• Serious herpes infections can affect the eyes. The medication guide identifies vision changes, eye redness and eye pain as possible signs and tells patients to contact their healthcare provider right away about an infection. Severe or persistent headache, stiff neck and confusion are other warning symptoms.
• PML is a rare, serious brain infection reported with ocrelizumab. It may cause worsening eyesight alongside changes in strength, balance, thinking or memory over days to weeks. Call your MS team right away about new or worsening neurological symptoms.

These warnings do not mean that every gritty or burning eye signals a serious infection. They explain why new symptoms should not simply be attributed to dryness. Medication guide and warnings

What may help mild dryness?

For mild dry-eye symptoms without the warning signs above, artificial tears are a common treatment. Screen breaks and avoiding direct wind, smoke or air-conditioning airflow may also help. These measures provide eye-surface relief; they do not treat optic neuritis or an infection. National Eye Institute

Our guide to choosing dry-eye drops explains liquids, gels, ointments and contact-lens compatibility.

If discomfort persists or returns, arrange an eye examination. Tell the eye-care professional that you receive Ocrevus Zunovo, when symptoms began relative to your injection, whether one or both eyes are affected, and which medicines, drops and contact lenses you use. Let your MS team know as well; decisions about delaying or changing treatment belong with the prescribing clinician.

This article provides general eye-health information, not a diagnosis or a complete guide to Ocrevus Zunovo’s risks.